Literature DB >> 11122725

Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.

P H Bowen1, J R Guyton.   

Abstract

Low levels of high-density lipoprotein cholesterol (HDL-C) constitute a strong risk factor for developing coronary heart disease. This risk can be decreased by even slight improvements in HDL-C levels. This review discusses both pharmacologic and nonpharmacologic treatments of patients with low levels of HDL-C, including lifestyle modifications and the benefits of oral estrogens, niacin, fibrates, statins, and combination drug therapy.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122725     DOI： 10.1007/s11883-000-0095-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.967


  43 in total

1.  Clofibrate and niacin in coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

2.  Prevalence of risk factors in men with premature coronary artery disease.

Authors:  J J Genest; J R McNamara; D N Salem; E J Schaefer
Journal:  Am J Cardiol       Date:  1991-06-01       Impact factor: 2.778

3.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

4.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

Authors: 
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

6.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport.

Authors:  G Assmann; H Schulte; A von Eckardstein; Y Huang
Journal:  Atherosclerosis       Date:  1996-07       Impact factor: 5.162

7.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

Authors:  W P Castelli; R J Garrison; P W Wilson; R D Abbott; S Kalousdian; W B Kannel
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

8.  High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners.

Authors:  P T Williams
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women.

Authors:  M J Stampfer; G A Colditz; W C Willett; F E Speizer; C H Hennekens
Journal:  N Engl J Med       Date:  1988-08-04       Impact factor: 91.245

Review 10.  Combination drug therapy for combined hyperlipidemia.

Authors:  J R Guyton
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 3.955
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.